Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing S... ( Extensive Clinical Development Pro...)

HOME >> MEDICINE >> NEWS

Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Date:6/27/2008

Extensive Clinical Development Program Investigating Golimumab in the

Treatment of These Diseases Serves as Basis for the Application

HORSHAM, Pa., June 27 /PRNewswire/ -- Centocor, Inc. announced today that a Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Golimumab, Centocor's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also being studied as an intravenous (IV) infusion therapy. In February 2008, Centocor submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting the approval of golimumab as a monthly subcutaneous treatment for the same indications.

"This submission marks a major milestone in the clinical development program of golimumab, and we look forward to working with the FDA to bring golimumab to market," said Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "We remain focused on our commitment to innovation in the field of biomedicines, to addressing the ongoing needs of patients living with these debilitating diseases and to physicians in need of additional therapeutic options to effectively treat their patients."

Five pivotal Phase 3 trials support the BLA, which include the GOlimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of Early onset (GO-BEFORE) study; the GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD) study; and A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Human Anti-TNF-alpha Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNF-alph
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
3. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
4. Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval
5. Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
6. Phyhealth Submits HMO Applications with Required Federal and State Agencies
7. Takeda submits new drug application for alogliptin (syr-322) in the US
8. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
9. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
10. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
11. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)

Post Your Comments:

Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing S...( Extensive Clinical Development Pro...),Health